| Nivoswitch trial: Predictive value of PD-L1 in plasma and extracellular vesicles. |
|
|
| J Clin Oncol 41 (no. 6_suppl): 718 |
|
2023 |
|
Nierenzellkarzinom
|
|
|
| ascopubs.org/doi/10.1200/JCO.2023.41.6_suppl.718 |
|
|
| Safety and efficacy of everolimus (EVE) as second-line treatment in neuroendocrine neoplasms G3 (NEN G3): An AIO phase II study (EVINEC). |
|
|
| Ann Oncol 34 (Supplement 2, S702, 1184MO) |
|
2023 |
|
Neuroendokrine Tumoren
|
|
|
| doi.org/10.1016/j.annonc.2023.09.717 |
|
|
| Analysis of efficacy and treatment pattern of second-line therapy after failure of immunotherapy-based treatment in recurrent or metastatic head and neck squamous cell carcinoma (r/m SCCHN) using the head and neck clinical research platform (HEAT). |
|
|
| Oncol Res Treat 46 (suppl.5): 244 |
|
2023 |
|
Kopf-Hals-Tumoren
|
|
|
| doi.org/10.1159/000533576 |
|
|
| Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212) |
|
|
| Eur J Cancer 178: 37-48 |
|
2023 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
|
|
| doi.org/10.1016/j.ejca.2022.09.011 |
|
|
| GOBLET: A phase 1/2 multiple indication study in advanced gastrointestinal cancers treated with pelareorep and atezolizumab – preliminary safety and efficacy results in second-line or later unresectable anal carcinoma |
|
|
| poster IMAAC 2023 |
|
2023 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
|
|
|
|
|
| Consensus Molecular Subtypes as Biomarkers of Fluorouracil and Folinic Acid Maintenance Therapy With or Without Panitumumab in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa, AIO KRK 0212). |
|
|
| J Clin Oncol 41(16): 2975-87 |
|
2023 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
|
|
| doi.org/10.1200/JCO.22.02582 |
|
|
| Impact of sex on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC). Subgroup analysis of the PanaMa-study (AIO-KRK-0212). |
|
|
| ESMO Open 8(4):101568 |
|
2023 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
|
|
| doi.org/10.1016/j.esmoop.2023.101568 |
|
|
| Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trials. |
|
|
| Eur J Cancer 190:112945 |
|
2023 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
|
|
| doi.org/10.1016/j.ejca.2023.112945 |
|
|
| Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab as maintenance therapy: a prespecified secondary analysis of the PanaMa (AIO KRK 0212) trial. |
|
|
| Eur J Cancer 190:112955 |
|
2023 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
|
|
| doi.org/10.1016/j.ejca.2023.112955 |
|
|
| Neoadjuvant mFOLFOX6 +/- Aflibercept in patients with T3-rectal cancer at low risk for local failure: a randomized phase II trial of the German Rectal Cancer Study Group (ACO/ARO/AIO 0214). |
|
|
| Oncol Res Treat 46 (suppl.5): 157 |
|
2023 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
|
|
| doi.org/10.1159/000533576 |
|
|
